Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
tmughal911@hotmail.com / tmughal@tuftsmedicalcenter.org.
Tariq I
TI
Mughal
Alessandro M
AM
Vannucchi
Simona
S
Soverini
Alexandra
A
Bazeos
Raoul
R
Tibes
Giuseppe
G
Saglio
Omar
O
Abdel-Wahab
Animesh
A
Pardanani
Rudiger
R
Hehlmann
Tiziano
T
Barbui
Richard
R
Van Etten
Ayalew
A
Tefferi
John M
JM
Goldman
D044127:Epigenesis, Genetic; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D058990:Molecular Targeted Therapy; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl; D053612:Janus Kinases